MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges
A Mansouri, LD Hachem, S Mansouri, F Nassiri… - Neuro …, 2019 - academic.oup.com
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally
poor prognosis. The emergence of molecular biomarkers has had a significant impact on …
poor prognosis. The emergence of molecular biomarkers has had a significant impact on …
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
B Kaina, M Christmann - DNA repair, 2019 - Elsevier
Alkylating agents have been used since the 60ties in brain cancer chemotherapy. Their
target is the DNA and, although the DNA of normal and cancer cells is damaged …
target is the DNA and, although the DNA of normal and cancer cells is damaged …
Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification
A Wenger, S Ferreyra Vega, T Kling, TO Bontell… - Neuro …, 2019 - academic.oup.com
Background A feature of glioblastoma (GBM) is cellular and molecular heterogeneity, both
within and between tumors. This variability causes a risk for sampling bias and potential …
within and between tumors. This variability causes a risk for sampling bias and potential …
Prognostic and predictive epigenetic biomarkers in oncology
K Kamińska, E Nalejska, M Kubiak, J Wojtysiak… - Molecular diagnosis & …, 2019 - Springer
Epigenetic patterns, such as DNA methylation, histone modifications, and non-coding RNAs,
can be both driver factors and characteristic features of certain malignancies. Aberrant DNA …
can be both driver factors and characteristic features of certain malignancies. Aberrant DNA …
Impact of H3. 3 K27M mutation on prognosis and survival of grade IV spinal cord glioma on the basis of new 2016 World Health Organization classification of the …
BACKGROUND Spinal cord glioma grade IV is a rare, diffuse midline glioma. H3 K27M-
mutant was classified in a different entity in the 2016 World Health Organization (WHO) …
mutant was classified in a different entity in the 2016 World Health Organization (WHO) …
Epigenetic regulation of DNA repair genes and implications for tumor therapy
M Christmann, B Kaina - Mutation Research/Reviews in Mutation Research, 2019 - Elsevier
DNA repair represents the first barrier against genotoxic stress causing metabolic changes,
inflammation and cancer. Besides its role in preventing cancer, DNA repair needs also to be …
inflammation and cancer. Besides its role in preventing cancer, DNA repair needs also to be …
Are there thresholds in glioblastoma cell death responses triggered by temozolomide?
Y He, B Kaina - International journal of molecular sciences, 2019 - mdpi.com
Temozolomide (TMZ) is an alkylating agent used in the treatment of high-grade malignant
glioma, notably glioblastoma multiforme, the most aggressive form of brain cancer. The drug …
glioma, notably glioblastoma multiforme, the most aggressive form of brain cancer. The drug …
DNA methylation and chromatin modifiers in colorectal cancer
V Vymetalkova, P Vodicka, S Vodenkova… - Molecular aspects of …, 2019 - Elsevier
Colorectal carcinogenesis is a multistep process involving the accumulation of genetic
alterations over time that ultimately leads to disease progression and metastasis. Binding of …
alterations over time that ultimately leads to disease progression and metastasis. Binding of …
Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas
F Gessler, JD Bernstock, A Braczynski, S Lescher… - …, 2019 - journals.lww.com
BACKGROUND Previous studies addressing the influence of surgery on the outcome of
patients with glioblastomas (GBM) have not addressed molecular markers. The value of …
patients with glioblastomas (GBM) have not addressed molecular markers. The value of …
The SIAH1–HIPK2–p53ser46 damage response pathway is involved in temozolomide-induced glioblastoma cell death
Y He, WP Roos, Q Wu, TG Hofmann, B Kaina - Molecular Cancer Research, 2019 - AACR
Patients suffering from glioblastoma have a dismal prognosis, indicating the need for new
therapeutic targets. Here we provide evidence that the DNA damage kinase HIPK2 and its …
therapeutic targets. Here we provide evidence that the DNA damage kinase HIPK2 and its …